Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

ArriVent BioPharma adds Kristine Peterson to its Board

EditorNatashya Angelica
Published 04/22/2024, 04:29 PM

In a recent move by ArriVent BioPharma, Inc. (NASDAQ: AVBP), the company announced on April 20, 2024, that Kristine Peterson has been appointed to its Board of Directors, effective immediately. Peterson, with a notable career spanning over three decades in the pharmaceutical industry, will serve as a Class III Director until the 2027 annual meeting of stockholders.

Peterson's extensive experience includes her most recent role as CEO of Valeritas, Inc., from 2009 to 2016. Her tenure at Johnson & Johnson (NYSE:JNJ) as Company Group Chair of the biotechnology group from 2006 to 2009 saw her oversee commercial, research and development, and biologics manufacturing for oncology, immunology, and cell therapy. She also held executive positions at Biovail Corporation and spent 20 years in senior roles at Bristol-Myers Squibb Company (NYSE:BMY).

Alongside her executive career, Peterson has been active in governance roles, serving on the boards of Enanta Pharmaceuticals (NASDAQ:ENTA) and Immunocore Holdings, with past board roles at ImmunoGen (NASDAQ:IMGN), Inc., Amarin (NASDAQ:AMRN) Corporation plc, EyePoint Pharmaceuticals (NASDAQ:EYPT), and Paratek Pharmaceuticals (NASDAQ:PRTK).

Her contributions to the industry also include advisory positions with the Healthcare Businesswomen’s Association and the Biotechnology Industry Organization (BIO) Board.

ArriVent BioPharma's Board has determined that Peterson qualifies as an independent director under the Nasdaq Stock Market’s governance listing standards and the rules of the Securities Exchange Act of 1934. The company confirmed that there are no undisclosed arrangements or conflicts of interest concerning Peterson's appointment. As of now, the Board has not assigned Peterson to any specific committees.

Peterson holds a B.S. and an M.B.A. from the University of Illinois at Urbana-Champaign. Her appointment is expected to bring valuable insight and leadership to ArriVent BioPharma as it continues to navigate the pharmaceutical landscape.

The company has not disclosed any further details regarding Peterson's role or potential committee assignments. This information is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.